Product Code: MRFR/Pharma/3484-CR
Market Overview
Medical Foods Market is anticipated to register a CAGR of 6.3% during the review period. The rising power of consistent ailments, creating energizing needs among people, and uncovering issues about prebiotics and probiotic things are driving market advancement.
Consistent afflictions, for instance, cardiovascular, neurological, urological, and overpowering ailments are growing from one side of the planet to the other. Heart issues are ending up being more typical than other persevering contaminations in view of a shortfall of dynamic work, being overweight, lamentable food, or having a family parentage.
Diabetes is maybe the most notable persevering illness, and its recurrence is reliably growing. For instance, according to World Prosperity Affiliation (WHO) estimations conveyed in 2019, diabetes is responsible for by and large 1.5 million passings and is the tenth top justification for death. Additionally, rising income in medical foods to supervise and control diabetic neuropathy and diabetes is supposed to drive market headway.
Market Segmentation
Vitamins and minerals, proteins, omega-3 fatty acids, isoflavones, phytosterols, and other nutrients are included in the segmentation of the medical foods market based on nutritional ingredients. Based on the method of administration, the Medical Foods Market is divided into oral and enteral segments. Pills, powder, and other items are included in the segmentation of the Market based on Form.
Chronic renal disease, nutritional deficiencies, neurological and psychological disorders, metabolic disorders, pain management, gastrointestinal disorders, orphan illnesses, and others are among the applications used to segment the medical foods market. Based on a distribution channel that comprises retail pharmacies, hospital pharmacies, e-commerce, and others, the Market is segmented.
Regional Insights
The North American medical foods market represented the biggest market share in 2022. This is because of the rising pervasiveness of ongoing sicknesses like diabetes, disease, cardiovascular problems, and others, the ascent in the reception of medical foods in the region, and the rising key organization and expanding speculation by key part in the region.
Europe's medical foods market represents the second-biggest market share because of the rising consciousness of the advantages of medical foods, the developing improvement of new details, for example, plant-based proteins and probiotics, and the rising maturing populace.
The Asia-Pacific medical foods market is supposed to develop a huge expansion because of the further developing medical care framework, rising geriatric populace and illnesses related to advanced age, and developing well-being mindfulness among the populace in the Asia-Pacific region.
The remainder of the World is sectioned into the Center East, Africa, and Latin America. The medical foods market in the previously mentioned regions is probably going to observe development because of further developing medical services offices, the developing accessibility of medical food items, and the rising predominance of constant illnesses like diabetes, malignant growth, and cardiovascular problems in these regions.
Major Players
Key Companies in the Medical Foods Market are Danone SA (France), Abbott (US), Fresenius Kabi AG (Germany), TARGETED MEDICAL PHARMA INC (US), Metagenics LLC (US), Nestle (Switzerland), Reckitt Benckiser Group PLC (UK), Medtrition, Inc (US), Primus Pharmaceuticals, inc (US), and Alfasigma USA, Inc (US).
TABLE OF CONTENTS
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.4 FORECASTING TECHNIQUES
- 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.5.1 BOTTOM-UP APPROACH
- 3.5.2 TOP-DOWN APPROACH
- 3.6 DATA TRIANGULATION
- 3.7 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
- 4.2.2 GROWING NUTRITIONAL DEFICIENCY AMONG PEOPLE
- 4.2.3 RAISING AWARENESS ABOUT PREBIOTICS AND PROBIOTIC PRODUCTS
- 4.3 RESTRAINTS
- 4.3.1 LACK OF AWARENESS REGARDING MEDICAL FOOD
- 4.4 OPPORTUNITIES
- 4.4.1 INCREASING PRODUCT LAUNCH INITIATIVES AND CONSTANT INNOVATIONS IN DEVELOPING PRODUCTS
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE GLOBAL MEDICAL FOODS MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON PRODUCTION
- 5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL MEDICAL FOODS MARKET, BY NUTRITIONAL INGREDIENTS
- 6.1 OVERVIEW
- 6.2 VITAMINS AND MINERALS
- 6.3 PROTEINS
- 6.4 OMEGA-3
- 6.5 ISOFLAVONES
- 6.6 PHYTOSTEROLS
- 6.7 OTHERS
7 GLOBAL MEDICAL FOODS MARKET, BY ROUTE OF ADMINISTRATION
- 7.1 OVERVIEW
- 7.2 ORAL
- 7.3 ENTERAL
8 GLOBAL MEDICAL FOODS MARKET, BY FORM
- 8.1 OVERVIEW
- 8.2 PILLS
- 8.3 POWDER
- 8.4 OTHERS
9 GLOBAL MEDICAL FOODS MARKET, BY APPLICATION
- 9.1 OVERVIEW
- 9.2 CHRONIC KIDNEY DISEASE
- 9.3 NUTRITIONAL DEFICIENCY
- 9.4 NEUROLOGICAL & PSYCHOLOGICAL DISORDERS
- 9.5 METABOLIC DISORDERS
- 9.6 PAIN MANAGEMENT
- 9.7 GASTROINTESTINAL DISORDERS
- 9.8 ORPHAN DISEASES
- 9.9 OTHERS
10 GLOBAL MEDICAL FOODS MARKET, BY DISTRIBUTION CHANNEL
- 10.1 OVERVIEW
- 10.2 E-COMMERCE
- 10.3 HOSPITAL PHARMACIES
- 10.4 RETAIL PHARMACIES
- 10.5 OTHERS
11 MEDICAL FOODS MARKET, BY REGION
- 11.1 OVERVIEW
- 11.2 NORTH AMERICA
- 11.3 EUROPE
- 11.3.1 GERMANY
- 11.3.2 UK
- 11.3.3 FRANCE
- 11.3.4 ITALY
- 11.3.5 SPAIN
- 11.3.6 REST OF EUROPE
- 11.4 ASIA-PACIFIC
- 11.4.1 JAPAN
- 11.4.2 CHINA
- 11.4.3 INDIA
- 11.4.4 SOUTH KOREA
- 11.4.5 AUSTRALIA
- 11.4.6 REST OF ASIA-PACIFIC
- 11.5 REST OF THE WORLD
- 11.5.1 MIDDLE EAST
- 11.5.2 AFRICA
- 11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
- 12.1 OVERVIEW
- 12.2 COMPETITIVE BENCHMARKING
- 12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MEDICAL FOODS MARKET
- 12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MEDICAL FOODS MARKET
- 12.5 KEY DEVELOPMENT ANALYSIS
- 12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 12.6.2 MERGER/ACQUISITION
- 12.6.3 EXPANSION/ INVESTMENT
- 12.7 MAJOR PLAYERS SALES ANALYSIS
- 12.8 MAJOR PLAYERS R&D ANALYSIS
13 COMPANY PROFILES
- 13.1 DANONE SA
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 FINANCIAL OVERVIEW
- 13.1.3 PRODUCTS OFFERED
- 13.1.4 KEY DEVELOPMENTS
- 13.1.5 SWOT ANALYSIS
- 13.1.6 KEY STRATEGIES
- 13.2 ABBOTT
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 FINANCIAL OVERVIEW
- 13.2.3 PRODUCTS OFFERED
- 13.2.4 KEY DEVELOPMENTS
- 13.2.5 SWOT ANALYSIS
- 13.2.6 KEY STRATEGIES
- 13.3 FRESENIUS KABI AG
- 13.3.1 COMPANY OVERVIEW
- 13.3.2 PRODUCTS OFFERED
- 13.3.3 KEY DEVELOPMENTS
- 13.3.4 SWOT ANALYSIS
- 13.3.5 KEY STRATEGIES
- 13.4 TARGETED MEDICAL PHARMA INC
- 13.4.1 COMPANY OVERVIEW
- 13.4.2 FINANCIAL OVERVIEW
- 13.4.3 PRODUCTS OFFERED
- 13.4.4 KEY DEVELOPMENTS
- 13.4.5 KEY STRATEGIES
- 13.5 METAGENICS LLC
- 13.5.1 COMPANY OVERVIEW
- 13.5.2 FINANCIAL OVERVIEW
- 13.5.3 PRODUCTS OFFERED
- 13.5.4 KEY DEVELOPMENTS
- 13.5.5 KEY STRATEGIES
- 13.6 NESTLE
- 13.6.1 COMPANY OVERVIEW
- 13.6.2 FINANCIAL OVERVIEW
- 13.6.3 PRODUCTS OFFERED
- 13.6.4 KEY DEVELOPMENTS
- 13.6.5 SWOT ANALYSIS
- 13.6.6 KEY STRATEGIES
- 13.7 RECKITT BENCKISER GROUP PLC
- 13.7.1 COMPANY OVERVIEW
- 13.7.2 FINANCIAL OVERVIEW
- 13.7.3 PRODUCTS OFFERED
- 13.7.4 KEY DEVELOPMENTS
- 13.7.5 SWOT ANALYSIS
- 13.7.6 KEY STRATEGIES
- 13.8 MEDTRITION, INC
- 13.8.1 COMPANY OVERVIEWS
- 13.8.2 FINANCIAL OVERVIEW
- 13.8.3 PRODUCTS OFFERED
- 13.8.4 KEY DEVELOPMENTS
- 13.8.5 KEY STRATEGIES
- 13.9 PRIMUS PHARMACEUTICALS, INC
- 13.9.1 COMPANY OVERVIEW
- 13.9.2 FINANCIAL OVERVIEW
- 13.9.3 PRODUCTS OFFERED
- 13.9.4 KEY DEVELOPMENTS
- 13.9.5 KEY STRATEGIES
- 13.10 ALFASIGMA USA, INC
- 13.10.1 COMPANY OVERVIEW
- 13.10.2 FINANCIAL OVERVIEW
- 13.10.3 PRODUCTS OFFERED
- 13.10.4 KEY DEVELOPMENTSS
- 13.10.5 KEY STRATEGIES
14 APPENDIX
- 14.1 REFERENCES
- 14.2 RELATED REPORTS